The EU approved Boey (trenibotulinumtoxinE), a serotype E neurotoxin for frown lines that works in about 8 hours and fades in 2 to 3 weeks. Not FDA-approved.
The European Commission approved Boey (trenibotulinumtoxinE), the first serotype E neurotoxin, for frown lines across 30 EEA countries on July 17, 2026. Boey acts within about eight hours and wears off in roughly two to three weeks. It is not FDA-approved and cannot be used in the United States.
Allergan Aesthetics, an AbbVie company, has received European Commission approval for Boey (trenibotulinumtoxinE), a botulinum toxin that works faster and fades sooner than the injectables most patients know. The July 17, 2026 clearance covers all 30 European Economic Area countries and makes Boey the first and only serotype E neurotoxin approved anywhere in Europe.
Boey is approved for the temporary improvement of moderate to severe glabellar lines, the vertical frown lines between the eyebrows, in adults. It is not FDA-approved and cannot be legally used in the United States. Health Canada cleared the same product in June 2026, but US availability remains uncertain.
Most neurotoxins on the market, including the FDA-approved Botox, Dysport, Xeomin and Jeuveau, use botulinum toxin type A, which typically takes several days to appear and lasts three to four months. Boey uses botulinum toxin type E, a different serotype that is taken up quickly by nerve cells and cleared quickly by the body, which gives it a fast onset and a short duration.
The approval rests on two Phase 3, randomized, double-blind, placebo-controlled trials, M21-500 and M21-508, in which 725 adults received either Boey 700 units or placebo. Onset was seen as early as eight hours after treatment, peak effect fell around day 7, and frown lines returned toward baseline within roughly two to three weeks. Reported adverse reactions were uncommon and included eyelid ptosis (0.17%), brow ptosis (0.13%) and a raised, arched brow known as the Mephisto sign (0.04%).
A neurotoxin that fades in weeks rather than months is a different product for a different shopper. Allergan positions Boey as a way to preview the look of a relaxed brow before committing to a longer-lasting type A toxin, or to time a smooth result around a specific event. The company cites survey data suggesting many consumers want a lower-commitment trial option before a permanent-feeling procedure.
For providers, that reframes the neurotoxin conversation from a single decision toward a menu of durations. This remains a European and Canadian development for now. injector.world does not rank or recommend any product, and the clinical evidence, not the marketing, defines what Boey does: fast on, fast off, for frown lines only.
Boey is not FDA-approved. In 2026 the FDA issued a Complete Response Letter on the US application, citing manufacturing issues rather than safety or efficacy concerns, so a US decision depends on Allergan resolving those issues and refiling. Anyone reading about Boey in US media should understand it is currently a European Union and Canadian product only.
The duration data also comes from two placebo-controlled trials focused on glabellar lines, so real-world longevity and any use beyond frown lines are not yet established. Anyone weighing neurotoxin options should talk with a licensed provider about which products are legally available and appropriate where they live.